Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate

Pharmacokinetics of drugs can be affected by physiologic changes during pregnancy. Our aim was to assess the influence of covariates on tenofovir (TFV) pharmacokinetics in pregnant and postpartum women receiving tenofovir disoproxil fumarate (TDF). ABSTRACT Pharmacokinetics of drugs can be affected by physiologic changes during pregnancy. Our aim was to assess the influence of covariates on tenofovir (TFV) pharmacokinetics in pregnant and postpartum women receiving tenofovir disoproxil fumarate (TDF). Population pharmacokinetic parameter estimates and the influence of covariates were assessed using nonlinear mixed-effects modeling (NONMEM 7.4). Forty-six women had intensive pharmacokinetic evaluations during the second and third trimesters of pregnancy, with another evaluation postpartum. A two-compartment pharmacokinetic model with allometric scaling for body weight and first-order absorption best described the tenofovir plasma concentration data. Apparent oral clearance (CL/F) and volume of distribution at steady state (Vss/F) were increased during pregnancy. Weight, serum creatinine (SCr), pregnancy, albumin, and age were associated with TFV CL/F during univariate assessment, but in the multivariate analysis, changes in CL/F and Vss/F were only associated with increased body weight and enhanced renal function. Due to greater weight and lower SCr during pregnancy, CL/F was 28% higher during pregnancy than postpartum. In the final model, CL/F (liters per hour) was described as 2.07 × (SCr/0.6)0.65 × weight0.75, with a low between-subject variability (BSV) of 24%. The probability of target attainment (proportion exceeding area under the concentration-time curve of >1.99 μg·h/ml, the 10th percentile of average TFV exposure for nonpregnant historical controls) was 68%, 80%, 87%, and 93% above the target with 300 mg, 350 mg, 400 mg, and 450 mg of TDF, respectively, during pregnancy and 88%, 92%, 96%, and 98% above the target with same doses in postpartum women. Dose adjustment of TDF during pregnancy is not generally warranted, but any modification should be based on weight and renal function. (This study has been registered at ClinicalTrials.gov under identifier NCT00042289.)

[1]  Dolutegravir Tivicay.  Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States , 2020 .

[2]  Myron S. Cohen,et al.  Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen , 2019, Clinical pharmacology and therapeutics.

[3]  P. Seed,et al.  Serum Creatinine in Pregnancy: A Systematic Review , 2018, Kidney international reports.

[4]  Linda J Harrison,et al.  Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus , 2018, Antimicrobial Agents and Chemotherapy.

[5]  S. Oka,et al.  Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1–Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort , 2017, AIDS patient care and STDs.

[6]  A. Ray,et al.  Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. , 2016, Antiviral research.

[7]  M. Mirochnick,et al.  Pharmacokinetics of tenofovir during pregnancy and postpartum , 2015, HIV medicine.

[8]  Maged M. Costantine,et al.  Physiologic and pharmacokinetic changes in pregnancy , 2014, Front. Pharmacol..

[9]  C. Leen,et al.  Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure , 2014, The Journal of infectious diseases.

[10]  B. Clotet,et al.  High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. , 2012, Antiviral research.

[11]  V. Esnault,et al.  Increased Time Exposure to Tenofovir Is Associated with a Greater Decrease in Estimated Glomerular Filtration Rate in HIV Patients with Kidney Function of Less than 60 ml/min/1.73 m2 , 2012, Nephron Clinical Practice.

[12]  J. Casado,et al.  Proximal tubular renal dysfunction or damage in HIV-infected patients. , 2012, AIDS reviews.

[13]  S. Urien,et al.  Pregnancy-Related Effects on Tenofovir Pharmacokinetics: a Population Study with 186 Women , 2011, Antimicrobial Agents and Chemotherapy.

[14]  C. Fletcher,et al.  Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected Patients , 2011, Antimicrobial Agents and Chemotherapy.

[15]  H. Yazaki,et al.  Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese Patients , 2011, PloS one.

[16]  M. Sánchez-Niño,et al.  Tenofovir Nephrotoxicity: 2011 Update , 2011, AIDS research and treatment.

[17]  V. D’Agati,et al.  Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. , 2010, Kidney international.

[18]  William A. Lee,et al.  Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. , 2009, Molecular pharmaceutics.

[19]  C. Fletcher,et al.  The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  F. Dabis,et al.  Population Pharmacokinetics of Tenofovir in HIV‐1‐Infected Pregnant Women and Their Neonates (ANRS 12109) , 2009, Clinical pharmacology and therapeutics.

[21]  S. Urien,et al.  Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy , 2008, Antimicrobial Agents and Chemotherapy.

[22]  B. Kearney,et al.  Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137 , 2007, Journal of acquired immune deficiency syndromes.

[23]  G. Chittick,et al.  Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers , 2007, Journal of clinical pharmacology.

[24]  K. Robinson,et al.  Mechanism of Active Renal Tubular Efflux of Tenofovir , 2006, Antimicrobial Agents and Chemotherapy.

[25]  M. Boffito,et al.  Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate , 2005, Antimicrobial Agents and Chemotherapy.

[26]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[27]  B. Kearney,et al.  Tenofovir Disoproxil Fumarate , 2004, Clinical pharmacokinetics.

[28]  F. Russel,et al.  The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. , 2002, Journal of the American Society of Nephrology : JASN.

[29]  J. Davison,et al.  The kidney and hypertension in pregnancy: twenty exciting years. , 2001, Seminars in nephrology.

[30]  T. Cihlar,et al.  Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. , 2000, Journal of the American Society of Nephrology : JASN.

[31]  W. Dunlop.  Renal physiology in pregnancy. , 1979, Postgraduate medical journal.